Linezolid Shortage Update: What Patients Need to Know in 2026

Linezolid (Zyvox) is an antibiotic used to treat some of the most dangerous drug-resistant infections. In 2026, patients and healthcare providers continue to face supply challenges with the intravenous (IV) form of this medication. This article provides the most up-to-date information on the shortage, which formulations are affected, what is available, and what patients can do right now.

Current Linezolid Shortage Status (2026)

As of 2026, the American Society of Health-System Pharmacists (ASHP) continues to list linezolid injection as an active drug shortage. The shortage was first created on October 16, 2024, and was last updated on October 30, 2025.

Specifically affected:

• Pfizer's Zyvox IV solution (2 mg/mL, 100 mL and 300 mL bags) — in limited supply due to manufacturing delays
• Hikma's linezolid injection (2 mg/mL, 300 mL bags) — shortage reason not disclosed

Currently available from:

• Eugia US — linezolid injection available
• Fresenius Kabi — linezolid injection available
• Piramal Critical Care — linezolid injection available
• Sandoz — linezolid injection available
• Sun Pharma — linezolid injection available

The oral tablet form (600 mg) and oral suspension (100 mg/5 mL) of linezolid are not listed in the active shortage and are more widely available at retail pharmacies.

What Is the History of the Linezolid Shortage?

Linezolid has been available in generic form since approximately 2015, when the original Zyvox patent expired. The presence of multiple generic manufacturers generally improves supply stability. However, sterile injectable antibiotics — including linezolid IV bags — remain particularly vulnerable to manufacturing disruptions because they require complex, tightly controlled production processes.

The current shortage beginning in October 2024 represents a specific disruption in IV supply chains, primarily traced to manufacturing delays at Pfizer and an unexplained shortage at Hikma. With five other manufacturers still active, this is a supply disruption rather than a complete market failure — but it creates real-world challenges for hospital pharmacists, home infusion providers, and patients.

Who Is Most Affected by the Linezolid Shortage?

The impact falls hardest on:

• Patients with VRE infections: Linezolid is the only FDA-approved antibiotic specifically for VRE. Patients with VRE have fewer alternatives than those with MRSA.
• Post-discharge patients on home IV linezolid: These patients depend on home infusion pharmacies sourcing specific IV bag formulations, which can be disrupted mid-course.
• Patients with MRSA pneumonia: Some guidelines recommend linezolid over vancomycin for MRSA lung infections; if IV linezolid is unavailable, oral linezolid is often a viable switch.

What Should Patients Do Right Now?

If you are currently on linezolid or have just received a new prescription, here is a clear action plan:

1. Do not stop taking linezolid abruptly. Stopping an antibiotic before completing the course can worsen your infection and contribute to antibiotic resistance.
2. Call your infusion pharmacy or home pharmacy immediately if your next supply has not arrived. Give them 24–48 hours notice if possible.
3. Ask about manufacturer substitution. If your pharmacy's usual supplier is short, ask if they can source from Eugia, Fresenius Kabi, Piramal, Sandoz, or Sun Pharma.
4. Ask your doctor if oral linezolid tablets are appropriate for your case, especially if IV bags are the specific issue.
5. Use medfinder to locate pharmacies near you that have the specific form of linezolid you need.

Will the Linezolid Shortage End Soon?

There is no publicly announced resolution date for the current Pfizer or Hikma shortage. Manufacturing delays at sterile injectable facilities can take several months to resolve depending on the nature of the problem. However, since five other FDA-approved manufacturers have available supply, the impact is mitigated for most patients if hospitals and pharmacies are proactive in sourcing alternatives.

For a deeper explanation of what is driving this and other antibiotic shortages, see our article on why linezolid is so hard to find in 2026.